Jennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $85,995.21. Following the completion of the transaction, the executive vice president now owns 4,038 shares in the company, valued at $239,978.34. The trade was a 26.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, November 11th, Jennifer Kayden Lee sold 66,861 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $4,434,890.13.

Rhythm Pharmaceuticals Trading Up 1.8 %

Shares of RYTM opened at $61.02 on Thursday. The stock has a market cap of $3.75 billion, a PE ratio of -14.09 and a beta of 2.14. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58. The stock has a 50 day simple moving average of $57.37 and a 200-day simple moving average of $53.19.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.07. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The firm had revenue of $33.20 million during the quarter, compared to analyst estimates of $32.52 million. During the same period in the prior year, the company posted ($0.76) earnings per share. The business’s revenue for the quarter was up 47.6% compared to the same quarter last year. On average, sell-side analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price objective on the stock. Needham & Company LLC boosted their price objective on shares of Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. The Goldman Sachs Group boosted their price target on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $69.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.09.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. SRS Capital Advisors Inc. lifted its holdings in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after purchasing an additional 400 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter worth approximately $328,000. Cannon Financial Strategists Inc. bought a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $560,000. Principal Financial Group Inc. boosted its holdings in shares of Rhythm Pharmaceuticals by 13.2% in the 4th quarter. Principal Financial Group Inc. now owns 36,884 shares of the company’s stock worth $2,065,000 after acquiring an additional 4,298 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new stake in Rhythm Pharmaceuticals during the 4th quarter worth approximately $1,960,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.